Hubbry Logo
Cold medicineCold medicineMain
Open search
Cold medicine
Community hub
Cold medicine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cold medicine
Cold medicine
Cold medicine
View on Wikipedia
from Wikipedia

Cough medicine
Cough medicine often contains cough suppressants and expectorants.
Other namesCough and cold medicine, cough syrup, lin, lean

Cold medicines are a group of medications taken individually or in combination as a treatment for the symptoms of the common cold and similar conditions of the upper respiratory tract. The term encompasses a broad array of drugs, including analgesics, antihistamines and decongestants, among many others. It also includes drugs which are marketed as cough suppressants or antitussives, but their effectiveness in reducing cough symptoms is unclear or minimal.[1][2][3]

While they have been used by 10% of American children in any given week, they are not recommended in Canada or the United States in children six years or younger because of lack of evidence showing effect and concerns of harm.[4][5] 

Types

[edit]

There are a number of different cough and cold medications, which may be used for various coughing symptoms. The commercially available products may include various combinations of any one or more of the following types of substances:[citation needed]

An example combination is guaifenesin with codeine.

Effectiveness

[edit]

The efficacy of cough medication is questionable, particularly in children.[6][3] A 2014 Cochrane review concluded that "There is no good evidence for or against the effectiveness of OTC [over the counter] medicines in acute cough".[1] Some cough medicines may be no more effective than placebos for acute coughs in adults, including coughs related to upper respiratory tract infections.[7] The American College of Chest Physicians emphasizes that cough medicines are not designed to treat whooping cough, a cough that is caused by bacteria and can last for months.[8] No over-the-counter cough medicines have been found to be effective in cases of pneumonia.[9] They are not recommended in those who have COPD, chronic bronchitis, or the common cold.[10][2] There is not enough evidence to make recommendations for those who have a cough in cancer.[11]

Medications

[edit]
  • Dextromethorphan (DXM) may be modestly effective in decreasing cough in adults with viral upper respiratory infections. However, in children, it has not been found to be effective.[12]
  • Codeine was once viewed as the "gold standard" in cough suppressants, but this position is now questioned.[13] Some placebo-controlled trials have found that it is ineffective against some forms of cough, including acute cough in children.[14][15] It is thus not recommended for children.[15][16] Additionally, there is no evidence that hydrocodone is useful in children.[17] Similarly, a 2012 Dutch guideline does not recommend its use to treat acute cough.[18]
  • A number of other commercially available cough treatments have not been shown to be effective in viral upper respiratory infections. These include for adults: antihistamines, antihistamine-decongestant combinations, benzonatate, anti asthmatic-expectorant-mucolytic combinations, expectorant-bronchodilator combinations, leukotriene inhibitors, ambroxol, and guaifenesin, sometimes with analgesics, antipyretics, anti inflammatories, and anticholinergics; and for children: antihistamines, decongestants for clearing the nose, or combinations of these and leukotriene inhibitors for allergy and asthma.[12][failed verification] However, antihistamines cannot be used as an empirical therapy in case of chronic, or non-specific cough, especially in very young children.[19] Long term diphenhydramine use is associated with negative outcomes in older people.[20]

Alternative medicine

[edit]

A small study found honey may be a minimally effective cough treatment due to "well-established antioxidant and antimicrobial effects" and a tendency to soothe irritated tissue.[21] A Cochrane review found there was weak evidence to recommend for or against the use of honey in children as a cough remedy.[22] In light of these findings, the Cochrane study found honey was better than no treatment, placebo, or diphenhydramine but not better than dextromethorphan for relieving cough symptoms.[22] Honey's use as a cough treatment has been linked on several occasions to infantile botulism and accordingly should not be used in children less than one year old.[23]

Many alternative treatments are used to treat the common cold, though data on effectiveness is generally limited. A 2007 review states that, "alternative therapies (i.e., Echinacea, vitamin C, and zinc) are not recommended for treating common cold symptoms; however, Vitamin C prophylaxis may modestly reduce the duration and severity of the common cold in the general population and may reduce the incidence of the illness in persons exposed to physical and environmental stresses."[24] A 2014 review also found insufficient evidence for Echinacea, where no clinical relevance was proven to provide benefit for treating the common cold, despite a weak benefit for positive trends.[25] Similarly, a 2014 systematic review showed that garlic may prevent occurrences of the common cold but there was insufficient evidence of garlic in treating the common cold and studies reported adverse effects of a rash and odour.[26] Therefore, more research needs to be done to prove that the benefits outweigh the harms.

Evidence supporting the effectiveness of zinc is mixed with respect to cough.[12] A 2003 review concluded: "Clinical trial data support the value of zinc in reducing the duration and severity of symptoms of the common cold when administered within 24 hours of the onset of common cold symptoms."[27] Zinc gel in the nose may lead to long-term or permanent loss of smell. The FDA therefore discourages its use.[28]

Recreational usage

[edit]
Main article: Lean (drug)

Cough medicines, especially those containing dextromethorphan and codeine, are often abused as recreational drugs.[29][30] Abuse may result in hallucinations, loss of consciousness and death. Many cough syrups can contain acetaminophen which will cause liver damage in recreational users.[30]

Adverse effects

[edit]

A number of accidental overdoses and well-documented adverse effects suggested caution in children.[23] The FDA in 2015 warned that the use of codeine-containing cough medication in children may cause breathing problems.[31] Cold syrup overdose has been linked to visual and auditory hallucinations as well as rapid involuntary jaw, tongue, and eye movements in children.[medical citation needed]

Decongestants are possibly harmful to people with high blood pressure or a heart disease because these substances can constrict the blood vessels.[32]

History

[edit]

Heroin was originally marketed as a cough suppressant in 1898.[33] It was, at the time, believed to be a non-addictive alternative to other opiate-containing cough syrups. This was quickly realized not to be true as heroin readily breaks down into morphine in the body. Morphine was already known to be addictive.[citation needed]

Society and culture

[edit]

Brands

[edit]

Some brand names include: Benylin, Sudafed, Robitussin and Vicks among others.[34] Most contain a number of active ingredients.[4] The Thai company Hatakabb produces the Takabb Anti-Cough Pill, which is a Chinese herbal medication.[35]

Sudafed is a brand owned by Kenvue.[36] Sudafed markets a variety of nasal decongestant products with different active ingredients in different countries. The original formulation contains the active ingredient pseudoephedrine. Other Sudafed-branded products contain phenylephrine,[37][38][39] oxymetazoline,[39][40] xylometazoline,[38] antihistamines, pain relievers, and other active ingredients. Product names and formulations vary by country. Restrictions on the sale of pseudoephedrine in the many countries has led to changes in which products are available over the counter without authorization from a pharmacist or prescriber. In 2016, Sudafed was one of the biggest selling branded over-the-counter medications sold in Great Britain, with sales of £34.4 million.[41]

Gee's Linctus is a cough medicine which contains opium tincture.[42] New Zealand in 2019 moved it to prescription only.[43]

Coricidin, Coricidin D, or Coricidin HBP, is the brand name of a combination of dextromethorphan and chlorpheniramine maleate (an antihistamine).[citation needed] Varieties may also contain acetaminophen and guaifenesin.[citation needed]

Codral is a brand name manufactured by Johnson & Johnson and sold primarily in Australia and New Zealand. Codral is the highest-selling cold and flu medication in Australia.[44]

Further information: Mollipect

Economics

[edit]

In the United States, several billion dollars are spent on over-the-counter products per year.[45]

Poisoning

[edit]
Main article: Toxic cough syrup

According to The New York Times, at least eight mass poisonings have occurred as a result of counterfeit cough syrup in which medical-grade glycerin has been replaced with diethylene glycol, an inexpensive, yet toxic, glycerin substitute marketed for industrial use. In May 2007, 365 deaths were reported in Panama, which were associated with cough syrup containing diethylene glycol.[46] In 2022, the deaths of 66 children in The Gambia were linked to four pediatric cough syrup medications that contained diethylene glycol and ethylene glycol.[47][48]

In 2022, the US Food and Drug Administration issued a warning against cooking foods in cough syrup after a video of someone preparing "NyQuil chicken", sometimes also called "sleepy chicken", became popular on social media. Cough syrup is designed to be stored at room temperature and its properties can change when it is heated, making it potentially deadly. Heated cough syrup can also vaporize, leading to inhalation hazards.[49][50][51] The warning received attention from many news outlets, but some criticized the FDA's handling of the issue for amplifying the attention the topic received online and questioned if making and eating NyQuil chicken actually existed as a widespread trend.[52][53][54]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cold medicine

View on Grokipedia
from Grokipedia
Cold medicines consist of over-the-counter formulations designed to mitigate symptoms of the , a self-limiting viral infection of the upper typically caused by rhinoviruses or coronaviruses, manifesting in , , , , and mild fever. These preparations do not eradicate the or shorten illness duration but target symptom relief via active ingredients including analgesics like acetaminophen for pain and pyrexia, decongestants such as for nasal patency, antitussives like for suppression, and expectorants like guaifenesin to facilitate clearance. Combination products dominate the market, often blending multiple agents to address polysymptomatic presentations, though from randomized controlled trials indicates variable ; for instance, oral decongestants provide modest short-term relief for congestion in adults, while antihistamines offer limited benefit unless allergic components are present. Analgesics effectively reduce fever and discomfort, but antitussives and expectorants lack robust support beyond in alleviating associated with uncomplicated colds. Regulatory scrutiny has highlighted safety concerns, particularly in pediatric populations, where the U.S. advises against using cough and cold medicines containing decongestants or antihistamines in children under two years due to risks of overdose, , and cardiovascular events outweighing negligible therapeutic gains. For children aged two to six, use remains discouraged absent physician guidance, reflecting post-marketing data on adverse events. Recent evaluations have also questioned the efficacy of longstanding ingredients like oral , deemed no more effective than for decongestion despite decades of approval.

Understanding the Common Cold

Etiology and Pathophysiology

The common cold is an acute infection of the upper respiratory tract caused by over 200 distinct viruses, primarily from families such as Picornaviridae, Coronaviridae, and Paramyxoviridae. Rhinoviruses, non-enveloped single-stranded RNA viruses belonging to the genus Enterovirus, are the predominant etiology, responsible for approximately 50% of cases in adults and children. Other notable contributors include endemic human coronaviruses (accounting for 10-15% of colds), respiratory syncytial virus (RSV), parainfluenza viruses, adenoviruses, and enteroviruses, with the precise viral agent varying by season, population, and geographic location. Bacterial superinfections are rare in uncomplicated colds and do not constitute the primary cause. Pathophysiologically, these viruses initiate infection by binding to specific receptors on the surface of ciliated epithelial cells in the and nasopharynx, the primary site of replication due to optimal (33-35°C) and receptor availability. For rhinoviruses, attachment occurs via intercellular adhesion molecule-1 () for major group serotypes or low-density lipoprotein receptor (LDLR) for minor group serotypes, followed by and uncoating in endosomes, enabling cytoplasmic replication and assembly of new virions. Viral progeny are released upon host cell , amplifying local infection while evading initial innate defenses through rapid replication cycles (typically 8-10 hours). This triggers a localized , including type I production and release (e.g., interleukin-6, interleukin-8, and tumor factor-alpha), which recruits neutrophils, macrophages, and T cells to the site. The ensuing drives key symptoms: and cause ; increased and goblet cell lead to and sneezing as mucociliary clearance mechanisms; and sensory nerve stimulation from and prostaglandins contributes to and . Unlike lower respiratory pathogens, viruses rarely invade beyond the superficial or bloodstream, limiting systemic symptoms; most manifestations arise from host-mediated rather than direct viral tissue destruction, explaining the self-limited course (typically 7-10 days). Genetic factors influencing receptor expression and immune profiles can modulate susceptibility and severity.

Epidemiology and Transmission

The , primarily caused by rhinoviruses and other respiratory viruses, affects adults an average of two to three times per year and preschool-aged children five to seven times per year, with incidence decreasing with age due to acquired immunity from repeated exposures. Globally, an estimated 17.2 billion cases occurred in 2019, representing a substantial portion of upper infections, which totaled 12.8 billion episodes excluding in 2021. Seasonal patterns show peaks in temperate regions during cooler, drier months—typically fall and winter in the —with infections highest in early fall and spring, though cases occur year-round. In tropical areas, incidence aligns more with rainy seasons, and low temperatures enhance viral survival on surfaces and in aerosols, contributing to winter epidemics in higher latitudes. Transmission occurs mainly through direct contact with infected respiratory secretions via hand-to-hand transfer or contaminated fomites, followed by self-inoculation to the or , rather than large-droplet s as the dominant route in indoor settings. Rhinoviruses can survive on fingers for hours, facilitating fomite-mediated spread, with rates of 70-80% among closely exposed individuals leading to symptomatic illness. While transmission is possible, experimental evidence indicates it is less efficient than contact routes in real-world scenarios.

Symptoms and Natural Course

The manifests primarily through upper symptoms, which emerge after an of 1 to 3 days following viral exposure. Initial prodromal signs often include sneezing, nasal discharge (), and a scratchy or , accompanied by mild systemic effects such as , low-grade fever (typically below 100.4°F or 38°C in adults), , and minor body aches. These early symptoms reflect the virus's replication in nasal and subsequent inflammatory response, without the high fevers or severe myalgias characteristic of . As the illness progresses, intensifies due to mucosal swelling and increased production, often peaking between days 2 and 4, while cough—initially dry and irritative—may develop or worsen from . Additional features can include watery eyes, sneezing paroxysms, and throat clearing, with symptom severity varying by viral strain (e.g., rhinoviruses predominate) and host factors like age or immune status; children experience more pronounced symptoms and complications such as . The natural course is self-limited, with most symptoms resolving within 7 to 10 days in immunocompetent adults, though and congestion may persist up to 2 weeks. Peak symptom intensity occurs around days 3 to 5, followed by gradual improvement as adaptive immunity clears the , without specific antiviral intervention required in uncomplicated cases. Prolonged duration beyond 10 days warrants evaluation for secondary bacterial infection or alternative diagnoses, as the primary illness does not typically extend absent comorbidities.

Pharmacological Treatments

Analgesics and Antipyretics

Analgesics and antipyretics are used in cold medicine to alleviate associated , such as , , and , and to reduce fever, which occurs in approximately 40-50% of cases due to the body's inflammatory response to viral infection. These agents do not target the underlying viral or shorten illness duration but provide symptomatic relief by modulating and hypothalamic . Over-the-counter doses are generally safe for adults and older children, with no evidence that they prolong or impair . Acetaminophen () acts centrally to inhibit synthesis, reducing fever and mild to moderate without significant anti-inflammatory effects. In adults with common colds, single doses of 1,000 mg have demonstrated superiority over in decreasing rhinorrhea severity, though benefits for sneezing, , or overall symptom scores are inconsistent across trials. A Cochrane review found limited high-quality evidence for its efficacy in colds specifically, but it remains a first-line option for fever and due to its favorable safety profile in standard doses up to 4 g daily for adults. Non-steroidal drugs (NSAIDs), such as ibuprofen, provide both and effects through peripheral and central inhibition of enzymes, additionally reducing that may contribute to or sinus discomfort. Systematic reviews indicate NSAIDs offer modest relief from general discomfort in colds but show no clear advantage for respiratory symptoms like or congestion compared to . In comparative studies of upper respiratory infections, ibuprofen (10 mg/kg dose) outperformed acetaminophen (15 mg/kg) in reducing fever and pain within 4-24 hours, particularly in children with infectious fevers, though differences were not always statistically significant for all subgroups. Aspirin is effective for pain and fever in adults at doses of 500-1,000 mg but is rarely recommended for colds due to gastrointestinal risks and its in children under 19 years owing to the association with Reye's syndrome in viral illnesses. Guidelines from bodies like the advise acetaminophen or ibuprofen for fever management in viral infections starting at age 6 months, emphasizing weight-based dosing (e.g., ibuprofen 5-10 mg/kg every 6-8 hours) to prioritize comfort over aggressive fever reduction, as fever itself aids viral clearance without routine necessity. Alternating acetaminophen and ibuprofen may enhance relief in persistent cases but lacks strong evidence of superiority and increases overdose risk if not monitored.
AgentTypical Adult Dose for Cold SymptomsKey Evidence for EfficacyPrimary Safety Concerns
Acetaminophen500-1,000 mg every 4-6 hours (max 4 g/day)Reduces and fever vs. ; inconsistent for other symptoms at >4 g/day; avoid in
Ibuprofen200-400 mg every 4-6 hours (max 1.2 g/day)Superior to acetaminophen for fever/pain in some pediatric trials; modest adult reliefGI upset, renal effects; avoid in or peptic history
Aspirin325-650 mg every 4-6 hours (avoid in children)Equivalent to other analgesics for pain/fever; not first-lineReye's syndrome risk in children; risk

Decongestants

Decongestants are pharmacological agents used to alleviate associated with the by promoting in the . They act primarily through stimulation of alpha-adrenergic receptors on vascular , leading to reduced blood flow, decreased mucosal swelling, and improved nasal airflow. Oral formulations, such as , achieve systemic effects, while topical nasal sprays, like , provide localized action with rapid onset, typically within minutes. Evidence from randomized controlled trials indicates that a single dose of nasal decongestants moderately relieves congestion symptoms in adults for short-term durations, with a reported 6% improvement in subjective congestion scores. For multiple doses, studies show a small beneficial effect on subjective nasal congestion measures, though objective improvements in nasal airway resistance are inconsistent and patient-perceived benefits remain unclear. Pseudoephedrine, in particular, has demonstrated superiority over placebo in reducing nasal congestion severity in upper respiratory tract infections, with efficacy observed in multicenter trials involving adults. Topical decongestants like offer quick relief but carry risks of , or rebound congestion, upon prolonged use beyond 3 days, characterized by worsened nasal inflammation due to and compensatory . This condition arises from overuse of alpha-adrenergic agonists, leading to increased nasal resistance after discontinuation. Oral decongestants avoid rebound effects but can elevate through systemic , posing risks for individuals with ; is contraindicated in uncontrolled and may cause modest increases even in controlled cases. Common adverse effects of oral decongestants include , nervousness, and , while topical agents may irritate . Decongestants do not shorten the duration of the but target symptom relief specifically for congestion, with limited evidence supporting their use in children under 12 years due to insufficient pediatric trials. Guidelines recommend short-term use only, typically 3-5 days for topicals and as needed for orals under medical supervision in at-risk populations.

Antitussives, Expectorants, and Antihistamines

Antitussives act by suppressing the cough reflex at the level of the medulla oblongata or peripherally on sensory nerves. Dextromethorphan, a common over-the-counter agent, is structurally related to opioids but lacks significant analgesic or addictive properties. A meta-analysis of studies on dextromethorphan at 30 mg doses versus placebo in acute upper respiratory tract infections found a significant reduction in subjective cough severity, though objective cough counts showed variable results influenced by strong placebo effects. However, a Cochrane review of over-the-counter medications for acute cough concluded there is no good evidence supporting their effectiveness over placebo in reducing cough frequency or severity in adults or children with upper respiratory infections. Expectorants aim to facilitate mucus clearance by increasing bronchial secretions and reducing sputum viscosity, often through hydration of respiratory secretions. Guaifenesin, the primary expectorant in use, has been evaluated in randomized trials for acute cough associated with upper respiratory tract infections. One review of clinical data indicated guaifenesin reduces cough frequency and intensity while improving mucus expectoration in patients with productive cough, with 96% of treated participants reporting decreased sputum thickness compared to 54% on placebo. Conversely, a controlled study measuring sputum volume and properties found no significant changes with recommended doses of guaifenesin, suggesting limited mucolytic action in acute settings. Overall, evidence supports modest symptomatic relief for mucus-related cough but lacks robust demonstration of physiological changes. Antihistamines, particularly first-generation H1 antagonists like diphenhydramine or chlorpheniramine, are included in some cold formulations to alleviate rhinorrhea and sneezing, though the common cold is primarily viral rather than allergic. A Cochrane systematic review of 18 randomized trials involving 4342 participants found antihistamines alone provide no significant relief for cough but offer modest reductions in sneezing and nasal discharge in adults, with effects more pronounced in first-generation agents due to anticholinergic properties. Second-generation antihistamines, such as loratadine, showed negligible benefits in rhinovirus challenge models. Combinations with decongestants and analgesics demonstrate greater overall symptom improvement than monotherapy, though isolated antihistamine use remains unsubstantiated for core cold symptoms. Sedation from first-generation agents limits their utility, especially in children.

Combination Products and Other Agents

Combination products for over-the-counter treatment of symptoms typically combine multiple active ingredients to target concurrent issues such as pain, congestion, cough, and . Common formulations include analgesics like acetaminophen (up to 650 mg per dose) or ibuprofen (200-400 mg) paired with decongestants such as (30-60 mg), antitussives like (10-30 mg), expectorants such as guaifenesin (200-400 mg), and occasionally first-generation antihistamines like chlorpheniramine (2-4 mg). These multi-ingredient preparations, exemplified by products containing , guaifenesin, and , aim to provide broad symptomatic relief but require careful label reading to avoid duplicative dosing when used alongside single-agent therapies. A key ingredient in many combination products has been oral (typically 5-10 mg per dose), intended as a nasal ; however, pharmacokinetic studies demonstrate negligible due to extensive first-pass , rendering it ineffective for relieving congestion when swallowed. In 2023, an FDA advisory committee unanimously concluded that oral phenylephrine lacks efficacy based on data spanning decades, prompting a 2024 proposal to remove it from OTC monographs while maintaining its approval for topical nasal sprays. Manufacturers have reformulated some products by substituting , which requires pharmacy purchase due to regulatory controls on its precursor status for synthesis. Other pharmacological agents beyond standard single-class or combination oral remedies include intranasal anticholinergics like ipratropium bromide (0.03-0.06% spray, 2-3 times daily), which reduce excessive runny nose by inhibiting glandular secretions without systemic vasoconstriction. Zinc acetate or gluconate lozenges (13-23 mg elemental zinc, taken every 2-3 hours for up to 5 days starting within 24 hours of symptom onset) modestly shorten cold duration by 1-2 days in adults via direct antiviral effects on rhinovirus replication in the nasopharynx, though gastrointestinal upset occurs in up to 30% of users. Pelargonium sidoides extract (standardized to 4.5% yield, 30 drops three times daily) has demonstrated reductions in symptom severity and duration by 1-2 days in randomized trials, potentially through antibacterial and immunomodulatory mechanisms, but data quality varies. Prescription options for severe cough include codeine (15-30 mg) or hydrocodone combinations, which suppress cough via central opioid receptors but carry risks of dependence and respiratory depression, limiting use to short-term in adults.

Evidence of Effectiveness

Symptom-Specific Relief from Pharmacological Agents

Oral decongestants, such as and , offer short-term relief from , a primary symptom of the caused by rhinovirus-induced and . A 2007 meta-analysis of randomized controlled trials demonstrated that a single 10 mg dose of significantly reduced subjective scores compared to , with peak effects observed at 90 minutes post-dosing in adults with acute symptoms. Similarly, a Cochrane of seven trials concluded that oral decongestants modestly alleviate congestion for up to 24 hours, though evidence for topical formulations is weaker due to risks like congestion, and overall benefits are not sustained beyond initial use. These effects stem from alpha-adrenergic reducing mucosal swelling, but efficacy diminishes in prolonged illness, and no decongestant shortens viral clearance. Analgesics and antipyretics target pain, fever, and associated with prostaglandin-mediated in the . Non-steroidal drugs (NSAIDs), including ibuprofen, provide superior relief for , , , and myalgias compared to , as evidenced by a 2015 Cochrane review of nine s showing statistically significant reductions in these analgesia-related symptoms within 1-2 days of treatment in adults. () similarly eases nasal obstruction and but shows limited impact on or systemic , per a 2020 review of two s, with benefits confined to early symptom phases without altering fever duration or intensity. These agents inhibit enzymes to curb inflammatory mediators, yet a 2014 randomized found regular dosing does not broadly mitigate cold progression beyond symptom palliation. Antihistamines address and driven by release in upper respiratory mucosa during viral . First-generation agents like chlorpheniramine yield minor short-term reductions in overall symptom severity on days 1-2 of treatment, particularly for nasal discharge, according to a 2015 Cochrane review of 16 trials, but second-generation options like loratadine show negligible effects, and benefits wane by day 3 with no influence on or congestion. Evidence from experimental challenges supports first-generation antihistamines for decreasing frequency and production via H1 receptor blockade, though monotherapy provides only marginal relief without addressing . Antitussives and expectorants aim to suppress or facilitate clearance of , often postnasal drip-induced in colds, but systematic indicates limited . A 2002 review of over-the-counter medicines found conflicting results for antitussives like , with some trials showing minor reductions in frequency but others no difference from , and no consistent impact on severity or duration. Expectorants such as guaifenesin may thin in productive s, as one small trial reported perceived decreases in thickness in 96% of treated patients versus 54% on , yet broader analyses, including a 2017 American College of Chest Physicians guideline, conclude insufficient to recommend them routinely for acute in viral upper respiratory infections. suppression via central agonism offers transient comfort but risks side effects without resolving underlying irritation. Combination products incorporating decongestants, analgesics, and antihistamines provide broader symptom relief than single agents in adults, with a 2022 Cochrane review of 26 trials reporting modest improvements in global symptom scores, though pediatric data remain sparse and high-quality trials are needed to confirm causality over effects. Overall, pharmacological relief is symptom-palliative and time-limited, supported by randomized primarily in otherwise healthy adults, with weaker substantiation for children or chronic users due to ethical trial constraints and variable viral strains.

Impact on Illness Duration and Severity

Over-the-counter cold medications, including analgesics, decongestants, antitussives, and antihistamines, do not shorten the duration of the , a self-limiting viral typically resolving in 7 to 10 days regardless of treatment. Systematic reviews confirm that these agents target symptoms without influencing or immune clearance, leaving the natural course unaltered. For instance, a Cochrane review of oral antihistamine-decongestant-analgesic combinations found modest benefits for overall symptom relief in adults but no of reduced illness duration. Regarding severity, these medications provide limited, short-term palliation rather than objective reductions in disease progression. Antipyretics like acetaminophen and ibuprofen alleviate fever and pain but neither prolong nor shorten total illness time, with meta-analyses showing no impact on acute duration. Decongestants, such as , offer transient relief—typically within hours of a single dose—but fail to mitigate broader severity or prevent complications like secondary bacterial . Antihistamines alone yield negligible effects beyond the first 1-2 days, per Cochrane analysis, underscoring their inefficacy for sustained severity control. Combination products, while marketed for multi-symptom relief, similarly lack robust data for altering severity trajectories. Reviews indicate small to moderate symptomatic improvements in older children and adults, but these do not translate to measurable decreases in peak symptom intensity or complication rates. Empirical trials emphasize that perceived severity reductions stem from targeted symptom masking, not causal intervention in , aligning with the absence of antiviral mechanisms in standard formulations. High-quality thus prioritizes these agents for comfort over curative claims, cautioning against expectations of shortened or lessened illness burden.

Non-Pharmacological and Alternative Approaches

Rest and adequate hydration are frequently recommended for managing symptoms, with the rationale that they support immune function and replace insensible fluid losses from fever and respiration. However, linking increased fluid intake to shortened illness duration remains limited, as a pilot found no association between upper infections and in adults. Similarly, while rest is advised to conserve energy for recovery, no randomized trials demonstrate it alters the natural course of rhinovirus-induced colds, which typically resolve in 7-10 days regardless. Saline nasal irrigation or drops offer symptomatic relief for in acute upper respiratory infections by mechanically clearing and potentially reducing postnasal drip-associated . A 2024 randomized trial in young children showed hypertonic saline drops shortened cold duration by approximately two days compared to no treatment. Systematic reviews indicate benefits for sinonasal symptom alleviation, though evidence on overall severity reduction is inconsistent, with some pediatric studies finding no significant impact. Proper technique using sterile or boiled water is essential to avoid rare infections from contaminated solutions. Honey provides effective relief for in upper infections, outperforming usual care or in multiple meta-analyses. A 2020 systematic of 14 trials concluded honey improves symptoms more than standard interventions, with particular efficacy in reducing nocturnal frequency and severity in children over one year old. Low-quality evidence from pediatric studies supports its use over no treatment for acute , though it should not be given to infants due to risk. Among alternative supplements, regular intake at doses of 1-2 grams daily modestly shortens duration by 8% in adults and 18% in children, while also lowering severity, according to Cochrane reviews analyzing over 11,000 participants across 29 trials. Therapeutic use at symptom onset shows no consistent benefit. preparations yield mixed results in randomized trials; while some report trends toward reduced incidence or duration in rhinovirus challenges, larger studies find no statistically significant effects on illness length or severity compared to . Overall, non-pharmacological approaches like these provide targeted symptom palliation but do not prevent or substantially abbreviate the phase of colds.

Safety and Risks

Common Adverse Effects

Common adverse effects of over-the-counter cold medicines are generally mild, transient, and dose-dependent, affecting a notable portion of users such as the 30% experiencing side effects like elevated pulse rate, diastolic , and in clinical studies of combination therapies. These effects arise primarily from the pharmacological actions of active ingredients, including stimulation or suppression, and gastrointestinal irritation, with antihistamine-decongestant-analgesic combinations showing significantly higher rates of adverse events compared to in randomized trials. Decongestants such as commonly cause , nervousness, anxiety, , restlessness, and mild increases in or , particularly when used beyond recommended durations of 3-5 days. Antihistamines like diphenhydramine or chlorpheniramine frequently induce drowsiness, dry mouth, , and due to their properties, with reported in up to 20-30% of users in symptomatic relief studies. Antitussives including may lead to , , , or stomach upset, while expectorants like guaifenesin are better tolerated but can occasionally produce , , or mild gastrointestinal symptoms such as . Analgesics and antipyretics, such as acetaminophen or ibuprofen, often result in gastrointestinal effects including , , or , especially with nonsteroidal drugs (NSAIDs) taken on an empty or in higher doses. In combination products, these effects can compound, increasing the likelihood of overlapping symptoms like or . Discontinuation typically resolves symptoms promptly, though individuals with sensitivities may experience effects at standard doses.

Drug Interactions and Contraindications

Over-the-counter cold medicines frequently contain multiple active ingredients, such as analgesics, decongestants, antitussives, and antihistamines, which can amplify the risk of interactions compared to single-agent therapies. These interactions may alter drug efficacy, exacerbate side effects, or precipitate serious adverse events like hypertensive crises or . Contraindications often stem from underlying conditions that heighten susceptibility, including , , and hepatic impairment. Decongestants like , commonly found in products for , are sympathomimetic agents that can interact with monoamine oxidase inhibitors (MAOIs), leading to potentially fatal hypertensive crises due to excessive norepinephrine release. They are also contraindicated in patients with uncontrolled , , or , as these agents may provoke arrhythmias or exacerbate . Additional interactions include additive effects with antidepressants or , potentially worsening cardiac outcomes. Antitussives such as , used for suppression, pose a risk of when combined with MAOIs or selective serotonin reuptake inhibitors (SSRIs), manifesting as agitation, hyperthermia, and neuromuscular abnormalities. This interaction arises from dextromethorphan's weak serotonin reuptake inhibition, which synergizes with serotonergic agents. Contraindications include concurrent use with these antidepressants, particularly in patients with a history of psychiatric disorders. Analgesics and antipyretics like acetaminophen interact adversely with alcohol, particularly in chronic consumers or at supratherapeutic doses, increasing the formation of the hepatotoxic metabolite N-acetyl-p-benzoquinone imide () and risking . Even therapeutic doses (up to 4 g/day) may elevate levels in heavy drinkers, though short-term moderate use typically poses lower risk. Contraindications apply to those with severe hepatic or active . Antihistamines in cold formulations, such as chlorpheniramine or diphenhydramine, exhibit additive when co-administered with alcohol, opioids, or other sedatives, heightening risks of drowsiness, respiratory depression, and impaired psychomotor function. First-generation agents are particularly prone to these effects due to blood-brain barrier penetration. They are contraindicated in patients with narrow-angle or from prostatic hypertrophy. In pediatric populations, many combination cold products are contraindicated for children under 6 years due to heightened toxicity risks from interactions and overdosing on ingredients like or . Overall, patients on chronic medications should consult healthcare providers, as in multi-symptom remedies can obscure hidden interactions.

Overdose, Poisoning, and Misuse

Overdose of medications primarily involves active ingredients such as (DXM), acetaminophen, , and antihistamines like diphenhydramine, leading to symptoms including respiratory depression, seizures, hallucinations, , and depending on the agent ingested. For DXM, high doses exceeding therapeutic levels (typically 15-30 mg per dose) can cause effects, agitation, , and , with severe cases progressing to or apnea. Acetaminophen-containing formulations, often combined with decongestants or antihistamines in multi-symptom products, pose a risk of ; doses above 4 grams daily in adults or even lower in children can result in , which accounts for nearly half of all cases in the United States. Treatment for overdose generally requires prompt gastric , supportive care, and specific antidotes like N-acetylcysteine for acetaminophen , with outcomes improving if intervention occurs within 8 hours of ingestion. Accidental from medicines disproportionately affects young children, often due to access to liquid formulations like syrups, with symptoms mirroring overdose effects but frequently milder if doses are sub-lethal. In the United States, poison control centers receive over 1 million annual calls related to pediatric exposures under age 5, with medications comprising a leading cause; however, fatalities from over-the-counter and products remain uncommon, primarily occurring in children under 2 years via ingestion leading to or . A review of pediatric cases found that over half involved agents known for severe , including antitussives in 20% of instances, underscoring the need for and storage precautions despite regulatory efforts like FDA advisories against use in children under 2 since 2008. While most exposures resolve without long-term harm, severe outcomes including death have been documented in clusters, such as three adverse events (one fatal) over 13 months from over-the-counter products. Misuse of cold medicine components extends beyond accidental overdose to intentional abuse, particularly DXM for its euphoric and hallucinogenic properties at supratherapeutic doses (300-1500 mg), often termed "robotripping" when extracted from syrups or tablets, leading to visits for acute intoxication. The monitors DXM due to rising abuse reports, though it remains unscheduled federally; five deaths have been linked to pure DXM abuse, typically involving high doses producing dissociative states akin to PCP. diversion for clandestine synthesis prompted the 2005 Combat Methamphetamine Epidemic Act, mandating behind-the-counter sales, purchase limits (e.g., 3.6 grams daily, 9 grams monthly), and record-keeping, which reduced small-scale "shake-and-bake" labs but shifted production dynamics without eliminating risks. These regulations reflect causal links between precursor availability and output, as evidenced by pre-2005 surges in diversion correlating with lab incidents.

Special Populations

Pediatrics

Concerns over adverse events from over-the-counter (OTC) cough and cold medications in children escalated in the early 2000s. A 2001 Pediatrics article reported three adverse outcomes, including one death, over 13 months from such use. Between 2004 and 2005, approximately 1,519 children under 2 years were treated in U.S. emergency departments for related adverse events, including suspected overdoses. In 2005, the Centers for Disease Control and Prevention (CDC) investigated three infant deaths (ages 1–6 months) in Maryland and Arizona attributed to overdoses involving pseudoephedrine, dextromethorphan, and antihistamines. The CDC published these findings in a 2007 Morbidity and Mortality Weekly Report (MMWR), while analyses in the Annals of Emergency Medicine reviewed FDA and poison control data, finding most fatalities occurred in children under 2 years from unintentional overdose. That year, an FDA advisory committee reviewed the evidence and voted against recommending use in children under 6 years. In 2008, manufacturers voluntarily relabeled products to contraindicate use under 4 years of age. The U.S. (FDA) advises against using over-the-counter (OTC) and medications containing decongestants or antihistamines in children under 2 years of age due to risks of serious and potentially life-threatening side effects, including overdose and respiratory depression. Children's bodies process medicines differently due to immature metabolism and excretion, making small overdoses easy and leading to side effects like rapid heart rate or drowsiness; many products combine multiple ingredients, increasing risks without proven benefits for young children. For children aged 2 to 4 years, the FDA recommends consulting a healthcare provider before use, as evidence of benefit is limited and risks remain elevated. The (AAP) concurs, recommending no OTC cough and cold medicines for children under 4 years, citing insufficient efficacy data and potential for harm such as sedation, agitation, or toxicity from ingredients like or diphenhydramine. For ages 4 to 6 years, use is discouraged except under direct medical supervision, with single-ingredient products preferred over multi-symptom combinations to minimize exposure. Under medical guidance, symptom-specific options may include second-generation antihistamines such as loratadine or cetirizine oral solutions for runny nose and sneezing, preferred over first-generation agents like chlorpheniramine due to reduced sedation risk; for significant nasal congestion, short-term use of pediatric pseudoephedrine (not exceeding 7 days and with caution in children under 6 years); and avoidance of compound cold medicines like acetaminophen-chlorpheniramine granules to prevent ingredient overlap and excess acetaminophen leading to liver damage. For fever, single-ingredient antipyretics such as acetaminophen or ibuprofen should be dosed by weight. Systematic reviews confirm scant evidence supporting OTC preparations for symptom relief in pediatric populations, with randomized trials often showing no superiority over for , congestion, or . Decongestants like carry risks of elevated , , and in young children, while antihistamines such as chlorpheniramine may induce drowsiness, paradoxical excitation, or effects, contributing to documented cases of and fatalities when dosed improperly or in unsupervised settings. Multi-ingredient formulations exacerbate these dangers through inadvertent overdose, as parents may administer multiple products unknowingly duplicating active ingredients. Non-pharmacological interventions are prioritized for pediatric cold management: nasal saline irrigation and suction for infants, humidified air, adequate hydration, and—for cough in children over 1 year—pasteurized honey (1–2.5 mL doses), which meta-analyses indicate provides modest antitussive benefits comparable to or exceeding certain OTC agents without adverse effects. Acetaminophen or ibuprofen may be used solely for fever or pain relief in appropriate doses, but not for core cold symptoms. Persistent symptoms warrant prompt medical evaluation to rule out complications like bacterial sinusitis or pneumonia, rather than reliance on unproven medications.

Adults with Comorbidities

Adults with comorbidities, such as , respiratory conditions, , or renal impairment, face heightened risks when using over-the-counter (OTC) cold medicines, as certain ingredients can exacerbate underlying pathologies. Decongestants like and , which constrict blood vessels to reduce , are contraindicated in patients with uncontrolled or heart disease due to their potential to elevate systolic by up to 20 mmHg even in normotensive individuals, with greater risks in those with preexisting elevations. Similarly, nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, commonly included for fever and pain relief, can increase and cardiovascular event risk, prompting recommendations to avoid them in this population. Acetaminophen remains a safer alternative for analgesia and antipyresis in cardiovascular patients, provided hepatic function is normal and doses do not exceed 4 grams daily to prevent . In individuals with respiratory comorbidities like or (COPD), first-generation antihistamines (e.g., chlorpheniramine) and cough suppressants (e.g., ) warrant caution, as they may thicken , impair clearance, and provoke or exacerbate wheezing, particularly if the cough is productive or stems from underlying inflammation rather than a simple viral infection. Guidelines advise against routine use of antitussives in chronic bronchitis or , where coughing serves a protective role in airway clearance, and recommend evaluating for triggers before administration. For diabetic patients, OTC cold remedies should exclude those with high sugar content or NSAIDs that could worsen nephropathy or ; -based products without added sugars are generally tolerable, but monitoring for glycemic effects from illness itself is essential. Renal and hepatic comorbidities further complicate use: NSAIDs are avoided in due to reduced glomerular filtration and risk of acute injury, while acetaminophen dosing must be adjusted in liver impairment to mitigate . Overall, evidence from clinical guidelines emphasizes physician consultation prior to , favoring single-ingredient formulations over multi-symptom combinations to minimize interactions, and prioritizing non-pharmacologic measures like hydration, humidification, and rest when feasible. Limited randomized trials specific to comorbid populations underscore that while symptomatic relief may parallel that in healthy adults, rates rise significantly, with up to 10-15% experiencing spikes from decongestants in hypertensive cohorts.

Pregnancy, Lactation, and Elderly

Pregnant individuals experiencing cold symptoms should prioritize non-pharmacological approaches, but when necessary, acetaminophen is considered safe for short-term use across trimesters, with no established link to increased birth defects in large cohort studies. , a common suppressant, shows low risk of adverse fetal outcomes when used occasionally, as minimal amounts cross the . First-generation antihistamines like chlorpheniramine have a favorable record, with meta-analyses indicating no significant association with congenital malformations. However, oral decongestants such as warrant caution, particularly in the first trimester, due to potential associations with specific defects like or small intestinal atresia in some observational data, though recent analyses of high-dose exposure found no overall elevated risk for major malformations. Combination products containing multiple agents, including those with , should be avoided to minimize unstudied interactions and unnecessary exposure. During lactation, acetaminophen remains compatible with breastfeeding, as only trace amounts enter breast milk and pose negligible risk to the . Dextromethorphan is similarly low-risk, with guidelines from lactation databases confirming minimal transfer and no reported adverse effects in breastfed s from short-term maternal use. Most over-the-counter cold remedies can be used judiciously for brief durations, but oral decongestants like are contraindicated due to evidence of reduced milk production, even after one or two doses, stemming from their vasoconstrictive effects on mammary tissue. First-generation s may cause infant drowsiness if highly sedating types are selected, prompting preference for second-generation options like loratadine when therapy is required. Consultation with a healthcare provider is advised to weigh benefits against potential infant exposure, particularly in preterm or medically fragile newborns where drug transfer risks are amplified. In elderly patients, physiological changes such as diminished renal and hepatic function lead to prolonged clearance, heightening risks from standard doses of cold medications. Antihistamines, especially first-generation ones like diphenhydramine, carry substantial risks of effects including , dry mouth, , , and increased falls due to and . Decongestants such as can exacerbate , arrhythmias, or issues, with case reports linking sympathomimetic-containing products to provoked seizures in this population. amplifies interactions, for instance, combining decongestants with antidepressants may precipitate hypertensive crises. Guidelines recommend lowest effective doses, single-ingredient formulations over combinations, and alternatives like saline irrigation to mitigate these vulnerabilities. For cold symptoms in elderly patients such as those aged 88 years, compound preparations like Compound Paracetamol and Amantadine Capsules should be avoided due to inefficacy of amantadine for common colds and heightened risks in this population; single-ingredient acetaminophen may be used for fever and pain with monitoring of total intake to prevent liver damage, alongside saltwater gargling or nasal irrigation for throat and nasal symptoms, rest, hydration, and temperature monitoring. Medical help should be sought if symptoms worsen, such as high fever or breathing difficulties, with any prescriptions tailored to specific health history, liver and kidney function, and other medications.

History

Pre-Modern Remedies

In , documented folk remedies for cold symptoms in his (circa 77–79 AD), including wolf liver steeped in , stewed , and horse saliva applied topically, alongside for throat irritation. These were empirical attempts to expel perceived humors or soothe inflammation, though lacking etiological understanding of viral causes. Around 60 AD, the Roman encyclopedist prescribed for cold sufferers, valuing its warmth and nourishment to aid recovery, a practice rooted in observational benefits like hydration rather than specific antiviral action. Medieval European treatments, influenced by Galenic humoral theory, emphasized restoring bodily balance through blood-letting and leeches to treat colds as imbalances of or . Herbal concoctions prevailed, such as root combined with comfrey for coughs and congestion, or syrups brewed from hyssop and figs for chest colds, administered to expectorate . For nasal symptoms, remedies included inhaling vapors from spiced fumigants or consuming mixtures of stale ale, ground , and mustard seeds to clear blockages and headaches. Cherry stones crushed and mixed with wine served as a pectoral for persistent coughs, reflecting shared human-animal therapeutic traditions. By the (16th–18th centuries), remedies incorporated more standardized herbals, such as elderberry syrups or teas from wormwood and cowslip to mitigate fever and duration, based on accumulated folk experience. therapies persisted, with pots of boiling herbs like or fumigated air spiced with cloves to decongest sinuses, alongside poultices of mustard or linseed for . These interventions, while varied, generally provided symptomatic relief through or expectorant effects but offered no cure, as viral etiology remained unknown until the ; many, like blood-letting, risked harm without proven benefit.

20th-Century Pharmaceutical Advancements

In the early decades of the 20th century, pharmaceutical efforts focused on analgesics and natural-derived sympathomimetics for cold symptom relief. Acetylsalicylic acid (aspirin), already available since 1899, gained widespread use for reducing fever and headache in cold sufferers, though its introduction predated the century. Ephedrine, isolated from the Ephedra sinica plant and introduced medically around 1924, served as an effective nasal decongestant by constricting blood vessels in the nasal mucosa, providing symptomatic relief without the sedation of earlier remedies. This marked a shift toward targeted vasoconstriction, though ephedrine's stimulant effects limited its standalone use. Mid-century advancements emphasized synthetic, non-opioid agents to address , congestion, and . Antihistamines emerged prominently after phenbenzamine's successful human testing in 1942 for allergic symptoms, with compounds like diphenhydramine (introduced 1946) later incorporated into cold formulations to mitigate sneezing and nasal discharge, despite limited evidence for viral colds. By 1955, acetaminophen entered clinical use as a safer analgesic-antipyretic alternative to aspirin, reducing risks of gastric irritation while effectively managing pain and fever. , patented in 1949 and approved for medical use in 1958, revolutionized suppression as the first non-narcotic antitussive, offering efficacy comparable to without potential. Decongestants advanced with , synthesized in the 1920s and established as a key oral sympathomimetic by the 1950s–1960s for sinus and relief in cold remedies. Combination products proliferated in the postwar era, integrating these agents (e.g., antihistamines with decongestants) for multi-symptom treatment, as evidenced by rising over-the-counter sales. However, clinical trials increasingly highlighted modest benefits confined to specific symptoms, with no impact on cold duration or , underscoring the era's focus on palliation rather than . Regulatory scrutiny intensified post-1962 Kefauver-Harris Amendments, prompting reviews that affirmed ingredients like while questioning others, such as certain antihistamines' role in non-allergic colds.

Recent Developments and Stagnation (2000–Present)

Since 2000, regulatory scrutiny has intensified on over-the-counter (OTC) cold medicines, particularly regarding safety in vulnerable populations. In 2007, the U.S. (FDA) issued a advisory recommending against the use of OTC cough and cold products in children under 2 years due to reports of serious adverse events, including convulsions and deaths, linked to overdosing; this was prompted by data from poison control centers documenting over 750,000 calls related to these products since 2000. Subsequent pediatric studies reinforced limited efficacy, leading to voluntary label changes by manufacturers and, by 2008, the withdrawal of infant formulations. These measures highlighted a shift toward evidence-based restrictions rather than therapeutic innovation. A major development in symptomatic relief came from re-evaluations of established decongestants. Oral , a staple in many multi-symptom cold remedies, faced mounting evidence of inefficacy; pharmacokinetic studies dating back to the early showed negligible after , rendering it no better than for . In 2023, an FDA advisory panel unanimously deemed it ineffective based on randomized controlled trials, culminating in a 2024 proposal to remove it from the OTC monograph for nasal decongestants, affecting products generating billions in annual sales. This followed restrictions on in 2005 under the Combat Methamphetamine Epidemic Act, which moved it behind pharmacy counters to curb diversion for illicit drug production, indirectly boosting reliance on less effective alternatives. Despite these adjustments, research into causal treatments for the —primarily rhinoviruses and other picornaviruses—has stagnated, with no novel antivirals or approved by the FDA since 2000. Over 200 rhinovirus serotypes, coupled with rapid mutation rates and the self-limiting nature of infections (typically resolving in 7–10 days), diminish commercial incentives for pharmaceutical investment, as development costs exceed potential returns for a mild illness. Early-2000s candidates like failed phase III trials due to variable efficacy across strains and safety concerns, such as inhibition leading to drug interactions. Preclinical advances, including a 2019 Stanford study demonstrating rhinovirus replication inhibition via host protein 2A blockade in human cells and mice, remain untranslated to clinical use, underscoring persistent barriers in host-targeted therapies. Symptom management research has yielded modest gains, with meta-analyses confirming lozenges (at doses ≥75 mg/day) shorten cold duration by about 33% when initiated within 24 hours of onset, though gastrointestinal side effects limit adoption. Intranasal ipratropium reduces runny nose but not congestion, per Cochrane reviews. However, broad-spectrum claims for , , or lack robust replication in large trials post-2000, reflecting a plateau where empirical data prioritizes supportive care—hydration, rest, and analgesics—over pharmacological cures. The indirectly advanced respiratory , but cold-specific pipelines show no phase III breakthroughs as of 2025, perpetuating reliance on pre-2000 formulations amid economic and biological hurdles.

Regulation and Policy

OTC Classification and Approval Processes

The (FDA) in the United States classifies cold medicines as over-the-counter (OTC) products when they meet criteria for general recognition as safe and effective (GRASE) for self-administration without medical oversight, primarily via the OTC monograph system initiated in 1972 to evaluate marketed ingredients through expert advisory panels and rulemaking. This system allows manufacturers to market compliant products without individual pre-approval, provided they adhere to specified active ingredients, dosages, indications (e.g., temporary relief of , congestion, or sneezing due to colds), labeling requirements, and testing standards outlined in . For cold medicines, key categories include antitussives (e.g., ), expectorants (e.g., guaifenesin), antihistamines (e.g., diphenhydramine), and nasal decongestants (e.g., topical or ), with conditions consolidated under 21 CFR Part 341. The primary governing OTC cold, , and drug products is M012, titled "Cold, , , , and Antiasthmatic Drug Products for Over-the-Counter Human Use," issued as an administrative order on October 14, 2022, under the Aid, Relief, and Economic Security ( of 2020, which replaced slower rulemaking with targeted FDA orders to accelerate updates based on new evidence. Historically, development involved separate rulemakings for components—such as the 1987 final for antitussives and ongoing reviews for antihistamines and decongestants—culminating in the comprehensive cough-cold final on December 23, 2002, which deemed certain ingredients GRASE based on clinical data submitted since the 1970s panels. Manufacturers of M012-compliant products must register facilities, list ingredients with the FDA, follow current good manufacturing practices (cGMP), and report adverse events, enabling post-market enforcement rather than upfront review. For ingredients or formulations outside monographs, including switches from prescription status or novel combinations, approval requires a (NDA) or (ANDA), with evidence of safety, efficacy, and consumer suitability via actual-use studies assessing labeling comprehension and misuse risks. An example is loratadine, approved for OTC marketing on November 27, 2002, under NDA 19-658/S-018 after demonstrated GRASE for allergy symptoms and adequate self-use in studies, marking one of the first major switches. Recent amendments underscore evidence-based reevaluation; on November 7, 2024, the FDA proposed excluding oral from M012 after decades of data, including dose-ranging trials and meta-analyses, showed it ineffective for nasal decongestion at 10 mg doses compared to , prioritizing empirical outcomes over historical inclusion.

Key Regulatory Changes and Controversies

In 2006, the U.S. Combat Methamphetamine Epidemic Act, part of the USA PATRIOT Improvement and Reauthorization Act, classified pseudoephedrine-containing cold medicines as scheduled list I chemicals, requiring retailers to place them behind the counter, verify purchaser identity with government-issued ID, maintain logs, and limit purchases to 3.6 grams per day and 9 grams per 30 days per individual to curb diversion for production. This change significantly restricted access to effective decongestants like , prompting manufacturers to reformulate products with alternatives such as , despite evidence of the latter's inferior efficacy. In January 2008, the FDA issued a advisory cautioning against the use of over-the-counter and products containing decongestants or antihistamines in children under 2 years old, citing over 1,200 visits, 2,000 calls to centers, and at least 3 deaths annually linked to overdoses or misuse in this age group from 2004–2005 data. In response, manufacturers voluntarily revised labels in October 2008 to contraindicate these products for children under 4, amid reports of serious adverse events including convulsions and cardiac arrhythmias, though causal links were often confounded by dosing errors or unsupervised administration rather than inherent toxicity at recommended doses. This regulatory shift highlighted tensions between parental demand for symptom relief and sparse of in young children, with subsequent studies questioning the overall benefits of such multi-ingredient formulations. In April 2017, the FDA contraindicated -containing cough syrups for children under 12 and those aged 12–18 post-tonsillectomy or , due to risks of life-threatening respiratory depression in ultra-rapid metabolizers, who convert to at excessive rates; post-marketing data identified at least 6 pediatric deaths and 24 cases of severe respiratory issues tied to this variability. Internationally, similar restrictions emerged, such as the UK's 2024 reclassification of linctus to prescription-only amid abuse concerns, reflecting broader controversies over misuse in non-prescription contexts despite 's modest antitussive effects supported by limited randomized trials. Most recently, in September 2023, a unanimous FDA advisory committee vote declared oral ineffective as a nasal at OTC doses, based on pharmacokinetic studies showing near-complete first-pass metabolism rendering systemic concentrations negligible—contradicting assumptions from its approval under less rigorous standards. In November 2024, the FDA proposed amending the OTC to remove oral , initiating a process for public comment through May 2025, potentially affecting billions in annual sales of products like Sudafed PE; while safe, its persistence stemmed from historical inertia rather than robust efficacy data, underscoring regulatory challenges in reevaluating legacy ingredients amid industry reliance on combination formulas. This move has sparked debate over consumer trust in labeled "decongestants" and the economic impact of reformulation, with critics noting that alternatives like topical or remain viable but less accessible.

Access Controls and Public Health Measures

In the United States, access to certain over-the-counter (OTC) cold medicines containing precursor chemicals has been restricted to mitigate their diversion for illicit production. The Combat Methamphetamine Epidemic Act of 2005, enacted as part of the USA PATRIOT Improvement and Reauthorization Act and signed into law on March 9, 2006, mandates that products with (PSE), , or be stored behind counters, require government-issued photo identification for purchase, and limit daily acquisitions to 3.6 grams of base chemical per buyer, with a 9-gram cap over 30 days. These measures include mandatory electronic logging of sales accessible to , reflecting that unrestricted PSE sales facilitated approximately 80-90% of small-scale meth labs prior to implementation, though federal policy stopped short of requiring prescriptions despite some state-level proposals. Similar controls apply to -containing remedies, classified as List I chemicals under the , with retail thresholds enforced to curb extraction for synthesis. Dextromethorphan (DXM), a common antitussive in cough syrups, faces state-level age-based access barriers to address adolescent recreational abuse, where high doses induce dissociative hallucinations akin to . As of 2018, 17 U.S. states, including Washington and , prohibit sales to individuals under 18 without proof of age, driven by surveys indicating 3-5% of teens misuse DXM annually for or sensory distortion, with risks of overdose including respiratory depression and . Federal efforts, such as the DXM Abuse Prevention Act of 2015, proposed nationwide 18+ restrictions and penalties for unfinished DXM distribution but failed to pass, leaving patchwork enforcement that has reduced but not eliminated youth access via proxies or online sources. Public health measures emphasize misuse prevention and safe application through regulatory advisories and monitoring. The U.S. (FDA) issued a 2008 public health advisory recommending against OTC cough and cold products for children under 2 years, citing meta-analyses showing no efficacy beyond for symptom relief and elevated risks of overdose, seizures, and in 1,200+ reported pediatric cases from 2004-2007. The FDA's Safe Use Initiative, launched in 2012, targets preventable harms from OTC medications via stakeholder collaborations, including revisions for dosing clarity and tamper-evident to deter , as evidenced by reduced tampering incidents post-mandate. For international contexts, the regulates and PSE under precursor control frameworks since 2012, requiring registration for quantities exceeding 100 grams to balance therapeutic access with diversion risks, while countries like cap personal imports at 21.6 grams to prevent abuse. These controls, grounded in data, prioritize causal links between unrestricted sales and adverse outcomes over unrestricted availability.

Societal and Economic Aspects

Marketing, Brands, and Consumer Behavior

The OTC cold medicine sector features prominent brands such as (), (), and (), and (), which collectively hold substantial market shares amid competition from generics. In the United States, the cough and cold remedies market reached approximately $12 billion in revenue by 2025, driven by seasonal demand and brand differentiation through multi-symptom formulations. Marketing strategies for these products emphasize (DTC) advertising, particularly television and digital campaigns highlighting rapid symptom relief and convenience during peak illness seasons. Pharmaceutical firms leverage and targeted online promotions to build trust in , often adapting to real-time illness trends for timely ad placements. The FDA regulates OTC ad claims to ensure truthfulness, prohibiting unsubstantiated statements while permitting promotion of approved uses like or effects. Consumer behavior reflects a preference for , with OTC cold remedies purchased impulsively at pharmacies or retailers during symptom onset, influenced heavily by prior ad exposure. Studies indicate that while 60% of favor branded products for perceived reliability, cost constraints lead many to opt for generics, which capture growing shares yet trail brands in familiar categories like suppressants where over 50% of sales remain branded. Brand persists due to factors like appeal, sensory attributes, and reference group endorsements, though price sensitivity and further shape dual-channel purchasing patterns.

Market Economics and Industry Dynamics

The global over-the-counter (OTC) cold and cough medicine market was valued at approximately USD 38.0 billion in 2024 and is projected to expand to USD 57.0 billion by 2034, reflecting a (CAGR) driven by persistent demand for symptom relief amid seasonal respiratory illnesses. In the United States, the cough and cold medicine sector reached USD 12.0 billion in market size as of 2025, underscoring the dominance of North American sales due to high consumer rates and widespread retail availability. Growth has been uneven, with a notably weak cough and cold season in 2023 limiting global OTC value sales increase to 3.9%, highlighting the sector's vulnerability to epidemiological fluctuations rather than consistent expansion. Major industry players include , which produces flagship brands like Tylenol Cold and Sudafed, alongside Benckiser (Mucinex) and (Vicks), commanding significant market share through established branding and distribution networks. Competition remains moderate but intensifying, with branded products facing pressure from generic entrants like those from and , which erode pricing power as generics capture volume in commoditized segments such as decongestants and expectorants. Economic dynamics favor high-margin OTC formulations, yet regulatory restrictions—such as behind-the-counter sales for pseudoephedrine-based products since 2006—have shifted competitive advantages toward alternative ingredients, reducing innovation incentives and fostering reliance on marketing over substantive R&D. Key growth drivers encompass rising incidences of respiratory infections, urbanization-induced , and consumer preferences for convenient self-treatment, bolstered by penetration that expanded access during the era. Challenges include generic proliferation, which compresses margins and prompts consolidation among manufacturers, alongside vulnerabilities exposed by shortages and geopolitical tensions affecting active pharmaceutical sourcing. Overall, the industry's oligopolistic sustains profitability for incumbents but stifles breakthroughs, as evidenced by stagnant profiles despite decades of market maturity, with economic incentives prioritizing incremental reformulations over causal cures for viral commons.

Cultural Perceptions and Usage Patterns

In Western cultures, particularly in and , cold medicines are predominantly perceived as convenient over-the-counter (OTC) solutions for symptom management, with high rates of self-medication reflecting trust in pharmaceutical efficacy despite limited evidence for curing viral infections. In the United States, consumers purchased approximately 242 million packages of oral OTC cough, cold, and allergy remedies in 2022, underscoring widespread reliance on products like decongestants and antihistamines for rapid relief. European surveys indicate similar patterns, with 76% of Polish respondents using synthetic OTC products for colds in the preceding year, often alongside herbal teas used by 30%. This contrasts with cultural preferences for physician consultation in , where self-medication rates for common colds remain low due to ingrained expectations of professional oversight, leading to clinic overcrowding during peak seasons. In many non-Western societies, perceptions emphasize humoral or environmental theories, attributing colds to imbalances like exposure to cold air or "cold" foods rather than solely viral transmission, influencing usage toward traditional remedies over modern pharmaceuticals. Indonesians, for instance, commonly invoke "cold weather theory" to explain colds and flu, prompting behaviors such as layering clothing or consuming warming substances to restore balance. In the Middle East, a study in Al-Medina Al-Munawara, Saudi Arabia, revealed a preference for herbal traditions, with honey cited as the primary remedy by a majority of respondents over conventional medicines, reflecting enduring faith in natural, . South Asian and Southeast Asian practices, drawing from and , favor herbs like , , and for their perceived antiviral and soothing properties, with self-medication patterns prioritizing these over synthetic options in rural or traditional communities. Global usage patterns exhibit seasonal spikes aligned with respiratory virus prevalence, but vary by access and cultural norms, with accounting for about 38% of consumers turning to OTC cold remedies during winter months. Latin American populations often blend folk conceptualizations—viewing colds as multifaceted afflictions involving or diet—with middle-class American-style OTC adoption, leading to hybrid practices. In , ethnic minorities may favor home-based therapies like rubs, perceived as culturally validated despite overlap with mainstream remedies. These differences highlight how source credibility influences perceptions: Western pharmaceutical marketing bolsters OTC dominance, while traditional systems persist in regions skeptical of industrialized medicine due to historical . Market data project the global and cough remedies sector at US$44.59 billion in 2025, driven by trends in high-income countries juxtaposed with slower uptake in traditionalist areas.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC10324571/
  2. https://www.uspharmacist.com/article/the-common-cold-a-review-of-otc-options
  3. https://www.aafp.org/pubs/afp/issues/2019/0901/p281.html
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC65295/
  5. https://journal.chestnet.org/article/S0012-3692%2817%2931408-3/fulltext
  6. https://www.fda.gov/consumers/consumer-updates/should-you-give-kids-medicine-coughs-and-colds
  7. https://www.fda.gov/drugs/information-drug-class/frequently-asked-question-childrens-cough-and-cold-medicines
  8. https://www.acs.org/pressroom/tiny-matters/fda-approved-phenylephrine-in-cold-medicines.html
  9. https://www.cdc.gov/common-cold/about/index.html
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC7150364/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC104573/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7152197/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4889530/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3378761/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7122998/
  16. https://www.uptodate.com/contents/the-common-cold-in-adults-diagnosis-and-clinical-features
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC7129474/
  18. https://www.sciencedirect.com/science/article/pii/S2772829324001140
  19. https://www.ncbi.nlm.nih.gov/books/NBK532961/
  20. https://emedicine.medscape.com/article/227820-overview
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC11357019/
  22. https://www.thelancet.com/journals/lancet/article/PIIS0140673603121629/fulltext
  23. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003194
  24. https://www.sciencedirect.com/science/article/pii/S0196655322008665
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC7129024/
  26. https://www.ajicjournal.org/article/S0196-6553%2822%2900866-5/pdf
  27. https://www.mayoclinic.org/diseases-conditions/common-cold/symptoms-causes/syc-20351605
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7185637/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC7109897/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC7125839/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC7112258/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC7389565/
  33. https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2710.2006.00754.x
  34. https://pubmed.ncbi.nlm.nih.gov/23818046/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10040208/
  36. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772373
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC8904092/
  38. https://www.sciencedirect.com/science/article/abs/pii/S1521691812000091
  39. https://www.aafp.org/pubs/afp/issues/2009/1215/p1472.html
  40. https://www.mayoclinic.org/diseases-conditions/fever/in-depth/fever/art-20050997
  41. https://health.ucdavis.edu/children/patient-education/fevers-in-children
  42. https://pubmed.ncbi.nlm.nih.gov/7507588/
  43. https://go.drugbank.com/drugs/DB00852
  44. https://pubmed.ncbi.nlm.nih.gov/15266459/
  45. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009612.pub2/full
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC6851811/
  47. https://www.ncbi.nlm.nih.gov/books/NBK538318/
  48. https://www.houstonmethodist.org/blog/articles/2022/mar/how-long-does-rebound-congestion-last-5-more-rebound-congestion-questions-answered/
  49. https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/expert-answers/high-blood-pressure/faq-20058281
  50. https://pubmed.ncbi.nlm.nih.gov/15794071/
  51. https://www.health.harvard.edu/heart-health/dont-let-decongestants-squeeze-your-heart
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC4985807/
  53. https://pubmed.ncbi.nlm.nih.gov/11591548/
  54. https://onlinelibrary.wiley.com/doi/abs/10.1002/ebch.314
  55. https://www.sciencedirect.com/science/article/abs/pii/S001236921536935X
  56. https://www.liebertpub.com/doi/10.4187/respcare.02640
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC5724298/
  58. https://www.cochrane.org/evidence/CD009345_antihistamines-common-cold
  59. https://academic.oup.com/cid/article/33/9/1483/413500
  60. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004976.pub4/full
  61. https://publications.aap.org/pediatrics/article/114/1/e85/64743/Effect-of-Dextromethorphan-Diphenhydramine-and
  62. pmc.ncbi.nlm.nih.gov/articles/PMC7366276/
  63. www.ama-assn.org/public-health/population-health/what-doctors-wish-patients-knew-about-which-cold-medicines-work
  64. www.fda.gov/news-events/press-announcements/fda-proposes-ending-use-oral-phenylephrine-otc-monograph-nasal-decongestant-active-ingredient-after
  65. www.pbs.org/newshour/show/why-the-fda-wants-to-pull-this-common-cold-medicine-ingredient-from-shelves
  66. www.ucsf.edu/news/2023/12/426791/why-you-might-not-find-your-favorite-cold-meds-pharmacy
  67. www.aafp.org/pubs/afp/issues/2019/0901/p281.html
  68. pmc.ncbi.nlm.nih.gov/articles/PMC3024156/
  69. pmc.ncbi.nlm.nih.gov/articles/PMC6026258/
  70. https://pubmed.ncbi.nlm.nih.gov/17692721/
  71. https://www.cochrane.org/evidence/CD006362_non-steroidal-anti-inflammatory-drugs-common-cold
  72. https://www.aafp.org/pubs/afp/issues/2014/0901/p335.html
  73. https://www.cochrane.org/evidence/CD004976_oral-antihistamine-decongestant-analgesic-combinations-common-cold
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC3928210/
  75. https://pubmed.ncbi.nlm.nih.gov/37142229/
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC6461189/
  77. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009345.pub2/full
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC351843/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC6823947/
  80. https://www.health.com/condition/cold/how-long-does-a-cold-last
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC9475221/
  82. https://www.ersnet.org/news-and-features/news/saline-nasal-drops-reduce-the-duration-of-the-common-cold-in-young-children-by-two-days/
  83. https://www.cureus.com/articles/317699-nasal-irrigation-with-saline-solution-for-pediatric-acute-upper-respiratory-infections-a-systematic-review
  84. https://www.fda.gov/consumers/consumer-updates/rinsing-your-sinuses-neti-pots-safe
  85. https://pubmed.ncbi.nlm.nih.gov/32817011/
  86. https://honey.com/images/files/Honey-URTI-Study_University-of-Oxford-2020.pdf
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC10570220/
  88. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000980.pub4/full
  89. https://pubmed.ncbi.nlm.nih.gov/23440782/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC3056276/
  91. https://journals.lww.com/ebp/fulltext/2015/04000/does_echinacea_prevent_and_treat_the_common_cold_.20.aspx
  92. https://jamanetwork.com/journals/jama/articlepdf/405816/jama_269_17_039.pdf?resultClick=1
  93. https://pmc.ncbi.nlm.nih.gov/articles/PMC8780136/
  94. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-q-and-a-decongestants-can-sometimes-cause-more-harm-than-good/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC11249067/
  96. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682492.html
  97. https://my.clevelandclinic.org/health/drugs/22078-expectorant
  98. https://www.webmd.com/cold-and-flu/cold-medicines-adults
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC2528730/
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC2257951/
  101. https://www.fda.gov/drugs/resources-drugs/drug-interactions-what-you-should-know
  102. https://www.mayoclinic.org/drugs-supplements/pseudoephedrine-oral-route/description/drg-20067942
  103. https://my.clevelandclinic.org/health/drugs/20768-pseudoephedrine-capsules-and-tablets
  104. https://www.nhs.uk/medicines/pseudoephedrine/who-can-and-cannot-take-pseudoephedrine/
  105. https://www.nhs.uk/medicines/pseudoephedrine/taking-pseudoephedrine-with-other-medicines-and-herbal-supplements/
  106. https://www.goodrx.com/dextromethorphan/interactions
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC5747823/
  108. https://www.healthline.com/health/drugs/dextromethorphan-interactions
  109. https://www.medicalnewstoday.com/articles/322813
  110. https://pubmed.ncbi.nlm.nih.gov/11776481/
  111. https://www.mayoclinic.org/diseases-conditions/alcoholic-hepatitis/symptoms-causes/syc-20351388
  112. https://www.goodrx.com/classes/antihistamines/interactions
  113. https://www.drugs.com/monograph/antihistamines-general-statement.html
  114. https://www.mayoclinic.org/drugs-supplements/chlorpheniramine-ibuprofen-and-pseudoephedrine-oral-route/description/drg-20526866
  115. https://www.ncbi.nlm.nih.gov/books/NBK538502/
  116. https://www.nlm.nih.gov/medlineplus/ency/article/002628.htm
  117. https://www.fda.gov/consumers/consumer-updates/dont-overuse-acetaminophen
  118. https://www.ncbi.nlm.nih.gov/books/NBK548162/
  119. https://pubmed.ncbi.nlm.nih.gov/36153206/
  120. https://www.nationwidechildrens.org/conditions/health-library/facts-about-poisons
  121. https://pubmed.ncbi.nlm.nih.gov/19101060/
  122. https://www.sciencedirect.com/science/article/pii/S2341287922001946
  123. https://pubmed.ncbi.nlm.nih.gov/11533370/
  124. https://pubmed.ncbi.nlm.nih.gov/19239735/
  125. https://www.justice.gov/archive/ndic/pubs11/11563/11563p.pdf
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC3793278/
  127. https://publications.aap.org/aapnews/article/27/5/8/21291/Law-restricts-access-to-pseudoephedrine-to-curb
  128. https://www.justice.gov/archive/ndic/pubs13/13853/product.htm
  129. https://publications.aap.org/pediatrics/article/108/3/e52/66608/Toxicity-of-Over-the-Counter-Cough-and-Cold
  130. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5601a1.htm
  131. https://www.annemergmed.com/article/S0196-0644(08)01779-4/abstract
  132. https://publications.aap.org/aapnews/article/29/1/13/22041/AAP-members-testify-at-FDA-hearing-on-use-of-cough
  133. https://www.fda.gov/drugs/special-features/use-caution-when-giving-cough-and-cold-products-kids
  134. https://publications.aap.org/pediatriccare/article/doi/10.1542/aap.ppcqr.396147/1495/Common-Cold
  135. https://www.healthychildren.org/English/health-issues/conditions/flu/Pages/caring-for-Your-childs-cold-or-flu.aspx
  136. https://elmstreetpediatrics.pediatrust.com/Guide-to-Your-Child-s-Medicines-A
  137. https://publications.aap.org/pediatrics/article/125/5/1125/72324/Cough-and-Cold-Medicines-Should-They-Be-Used-in
  138. https://www.mayoclinic.org/healthy-lifestyle/childrens-health/in-depth/cold-medicines/art-20047855
  139. https://publications.aap.org/pediatrics/article/139/6/e20163070/38712/Safety-Profile-of-Cough-and-Cold-Medication-Use-in
  140. https://publications.aap.org/patiented/article/doi/10.1542/ppe_schmitt_061/82369/Coughs-and-Colds-Medicines-or-Home-Remedies
  141. https://www.aafp.org/pubs/afp/collections/choosing-wisely/56.html
  142. https://pmc.ncbi.nlm.nih.gov/articles/PMC4500855/
  143. https://www.heart.org/en/news/2019/01/18/taking-medicine-for-a-cold-be-mindful-of-your-heart
  144. https://www.uspharmacist.com/article/respiratory-problems-and-nonprescription-products
  145. https://www.medicalnewstoday.com/articles/16181
  146. https://www.drugs.com/medical-answers/cold-medicine-you-diabetes-3564910/
  147. https://www.singlecare.com/blog/cold-medicine-for-high-blood-pressure/
  148. https://www.michiganmedicine.org/health-lab/why-high-blood-pressure-and-cold-meds-dont-mix
  149. https://uihc.org/educational-resources/cold-and-flu-medications-pose-risks-those-high-blood-pressure
  150. https://www.aafp.org/pubs/afp/issues/2003/0615/p2517.html
  151. https://www.goodrx.com/conditions/pregnancy/cold-medicine-safe-for-pregnancy
  152. https://www.aafp.org/pubs/afp/issues/2014/1015/p548.html
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC3816336/
  154. https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70001
  155. https://www.vcuhealth.org/services/womens-health/our-services/pregnancy-and-birth/resources/cold-and-flu-medications-in-pregnancy/
  156. https://infantrisk.com/content/cough-cold-medications-while-breastfeeding
  157. https://www.ncbi.nlm.nih.gov/books/NBK501922/
  158. https://www.breastfeedingnetwork.org.uk/factsheet/cold-remedies/
  159. https://health.clevelandclinic.org/breastfeeding-safe-medications
  160. https://www.mayoclinic.org/healthy-lifestyle/infant-and-toddler-health/in-depth/breastfeeding-and-medications/art-20043975
  161. https://www.fda.gov/drugs/tips-seniors/you-age-you-and-your-medicines
  162. https://www.healthinaging.org/tools-and-tips/learn-more-ten-medications-older-adults-should-avoid-or-use-caution
  163. https://cchphealthplan.com/medicine-risks-for-older-adults/
  164. https://pmc.ncbi.nlm.nih.gov/articles/PMC10148391/
  165. https://www.ormondmanor.com/post/5-tips-for-choosing-safe-cold-medicine-for-seniors
  166. https://www.mayoclinic.org/drugs-supplements/amantadine-oral-route-injection-route/description/drg-20061695
  167. https://www.mayoclinic.org/diseases-conditions/common-cold/in-depth/cold-remedies/art-20046403
  168. https://www.mebondbooks.com/2021/12/13/historic-treatments-for-the-common-cold/
  169. https://www.sandrawagnerwright.com/seldom-effective-cold-remedies-through-the-ages/
  170. https://www.bbc.com/news/magazine-15095924
  171. https://pmc.ncbi.nlm.nih.gov/articles/PMC3573364/
  172. https://www.nationalarchives.gov.uk/explore-the-collection/stories/a-medieval-cold-and-flu-remedy/
  173. https://blog.nationalmuseum.ch/en/2025/07/medieval-veterinary-medicine/
  174. https://www.osgf.org/blog/2020/1/8/historys-flu-fighting-plants
  175. https://www.londonmuseum.org.uk/blog/17th-century-post-medieval-cold-remedies/
  176. https://www.nejm.org/doi/full/10.1056/NEJMp0707400
  177. https://pmc.ncbi.nlm.nih.gov/articles/PMC3461939/
  178. https://www.fda.gov/news-events/press-announcements/fda-proposes-ending-use-oral-phenylephrine-otc-monograph-nasal-decongestant-active-ingredient-after
  179. https://www.theatlantic.com/health/archive/2023/09/cold-medicine-decongestant-phenylephrine-ineffective/675303/
  180. https://www.scientificamerican.com/article/why-havent-we-cured-the-common-cold-yet/
  181. https://pubmed.ncbi.nlm.nih.gov/11354808/
  182. https://med.stanford.edu/news/all-news/2019/09/in-human-cells-and-mice-a-cure-for-the-common-cold.html
  183. https://www.popsci.com/health/common-cold-100-years/
  184. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/historical-status-otc-rulemakings
  185. https://www.congress.gov/crs-product/R46985
  186. https://www.fda.gov/drugs/otc-drug-review-process-otc-drug-monographs
  187. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341
  188. https://www.federalregister.gov/documents/2002/12/23/02-32158/cold-cough-allergy-bronchodilator-and-antiasthmatic-drug-products-for-over-the-counter-human-use
  189. https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=monograph&OTC=M012
  190. https://www.fda.gov/drugs/historical-status-otc-rulemakings/rulemaking-history-otc-antitussive-drug-products
  191. https://www.fda.gov/drugs/how-drugs-are-developed-and-approved/over-counter-otc-nonprescription-drugs
  192. https://www.fda.gov/drugs/types-applications/drug-application-process-nonprescription-drugs
  193. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/19-658S018_Claritin_Medr_P1.pdf
  194. https://www.federalregister.gov/documents/2024/11/08/2024-25910/amending-over-the-counter-monograph-m012-cold-cough-allergy-bronchodilator-and-antiasthmatic-drug
  195. https://www.deadiversion.usdoj.gov/meth/cma2005.html
  196. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5743a5.htm
  197. https://www.npr.org/2008/10/08/95501981/no-cold-medicine-for-kids-under-4-new-labels-say
  198. https://pmc.ncbi.nlm.nih.gov/articles/PMC8586901/
  199. https://www.bmj.com/content/384/bmj.q456
  200. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-results-recent-advisory-committee-meeting-oral-phenylephrine
  201. https://www.fda.gov/drugs/understanding-over-counter-medicines/key-information-about-nonprescription-over-counter-otc-oral-phenylephrine
  202. https://www.aafp.org/pubs/afp/afp-community-blog/entry/FDA-advisory-panel-rules-that-oral-phenylephrine-is-ineffective.html
  203. https://www.pharmacytimes.com/view/combat-methamphetamine-epidemic-act-of-2005-takes-aim-at-drug-crisis
  204. https://www.cdc.gov/phlp/docs/pseudo-brief112013.pdf
  205. https://www.deadiversion.usdoj.gov/meth/combat-methamphetamine-epidemic-act.html
  206. https://insights.citeline.com/PS124147/States-With-Age-Restriction-On-OTC-DXM-Sales-Number-17--And-Counting/
  207. https://doh.wa.gov/licenses-permits-and-certificates/facilities-z/pharmacies/laws/dextromethorphan-product-list
  208. https://www.webmd.com/parenting/teens-cough-medicine-abuse
  209. https://www.govinfo.gov/content/pkg/CRPT-114hrpt672/html/CRPT-114hrpt672.htm
  210. https://www.fda.gov/drugs/drug-safety-and-availability/safe-use-initiative
  211. https://www.fda.gov/drugs/understanding-over-counter-medicines/over-counter-medicines-whats-right-you
  212. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:52012PC0521
  213. https://www.hsa.gov.sg/personal-medication/overview
  214. https://www.lincolninternational.com/perspectives/articles/over-the-counter-drug-trends-and-ma-in-2025/
  215. https://www.archivemarketresearch.com/reports/otc-cough-and-cold-and-allergy-medicine-338361
  216. https://www.ibisworld.com/united-states/industry/cough-cold-medicine-manufacturing-otc/4117/
  217. https://www.statista.com/outlook/hmo/otc-pharmaceuticals/cold-cough-remedies/united-states
  218. https://www.iqvia.com/blogs/2018/02/the-cold-and-flu-conundrum-getting-it-right
  219. https://viseven.com/pharmaceutical-digital-marketing-strategies-for-otc-brands/
  220. https://wjpsronline.com/images/eaa00962a963cf039dd475fc0278fb80.pdf
  221. https://www.fda.gov/drugs/prescription-drug-advertising/prescription-drug-advertising-questions-and-answers
  222. https://www.tandfonline.com/doi/abs/10.1179/2047971913Y.0000000032
  223. https://fortune.com/well/article/brand-name-vs-generic-drugs-prescription-over-the-counter-medications-cost-effectiveness/
  224. https://www.tebra.com/theintake/healthcare-reports/patient-treatment/generic-vs-name-brand
  225. https://www.montana.edu/carrera/documents/Carrera_Villas-Boas_incl_Appendix.pdf
  226. https://www.suzy.com/insights-blog/otc-healthcare-consumer
  227. https://www.researchgate.net/publication/361580382_Effective_Determinants_of_Consumer_Buying_Decision_on_OTC_Medications_Digital_Marketing_Brand_Experience_and_Reference_Groups
  228. https://www.reportsanddata.com/report-detail/otc-cold-and-cough-medicine-market
  229. https://www.iqvia.com/blogs/2024/04/poor-cough-and-cold-season-restricts-otc-growth-in-2023
  230. https://www.coherentmarketinsights.com/blog/insights/key-competitors-over-the-counter-drugs-industry-560
  231. https://www.linkedin.com/pulse/us-cold-medicine-market-unveiling-competitive-dynamics-future-driven-vmlqc
  232. https://www.linkedin.com/pulse/cough-medicine-market-key-insights-drivers-trends-challenges-zqlbc/
  233. https://datahorizzonresearch.com/otc-cough-and-cold-and-allergy-medicine-market-41385
  234. https://cen.acs.org/pharmaceuticals/campaign-effective-cold-cough-medicines/101/i39
  235. https://pmc.ncbi.nlm.nih.gov/articles/PMC7120590/
  236. https://onlinelibrary.wiley.com/doi/full/10.1002/jgf2.81
  237. https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2021.734044/full
  238. https://www.researchgate.net/publication/385409110_The_usage_of_traditional_remedies_in_comparison_with_medical_remedies_for_the_common_cold_in_Al-Medina_Al-Munawara
  239. https://pmc.ncbi.nlm.nih.gov/articles/PMC10278442/
  240. https://www.globalgrowthinsights.com/market-reports/cold-remedies-market-118186
  241. https://www.researchgate.net/publication/277361120_Cross-Cultural_Perspectives_on_the_Common_Cold_Data_from_Five_Populations
  242. https://jamanetwork.com/journals/jamapediatrics/fullarticle/190065
  243. https://www.statista.com/outlook/hmo/otc-pharmaceuticals/cold-cough-remedies/worldwide
Add your contribution
Related Hubs
User Avatar
No comments yet.